Cancer Trials / Trials in Louisiana
211 Recruiting Trials

Clinical Trials
for Cancer in Louisiana

211 clinical trials for Cancer are currently recruiting participants at study sites in Louisiana. Study-related care is provided at no cost.

211
Recruiting trials
179
Study sites
19
Cities
123
Industry-sponsored
62
Phase 2
104
Phase 3

Cancer clinical trials in Louisiana: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Louisiana, recruiting cancer studies are concentrated in New Orleans, Baton Rouge, Shreveport and Metairie, with sites in 15 other cities. 123 of the 211 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 211 recruiting Cancer trials in Louisiana

Prospective Study to Assess a Diagnostic Aid for Cancer
N/A Coronado, California +4 sites NCT07046260
This trial is looking for people aged 45 and older who have symptoms that might suggest cancer. Participants will take a blood test and may also have additional standard tests to see if cancer is present.
Recruiting
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
PHASE3 Jonesboro, Arkansas +4 sites NCT07391774
This trial is looking for women who are postmenopausal and have high stage breast cancer that is less likely to come back. Participants will compare hormone therapy and ribociclib to chemotherapy followed by hormone therapy and ribociclib.
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
PHASE3 Mobile, Alabama +4 sites NCT07472517
This trial is looking for adults with advanced small cell lung cancer. Participants will receive either a study medicine called obrixtamig along with standard treatment or just the standard treatment alone. The goal is to see if the study medicine helps improve survival.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
PHASE3 Anchorage, Alaska +4 sites NCT07062965
This trial is looking for people with HR-positive, HER2-negative advanced breast cancer that has worsened after previous treatment. Participants will receive the study medicine PF-07248144 along with their normal treatment options to see how well they work together.
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
PHASE3 Dothan, Alabama +4 sites NCT07611110
This trial is looking for men with advanced prostate cancer that hasn't responded to standard treatments. Participants will receive AZD2265 to see if it works better than standard care.
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
PHASE3 Los Angeles, California +4 sites NCT06340568
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
PHASE3 Shreveport, Louisiana +4 sites NCT07816666
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
PHASE3 Little Rock, Arkansas +4 sites NCT06312137
This trial is looking for adults with a type of lung cancer called non-small cell lung cancer who did not have a complete response after surgery. Participants will receive medications to see if adding sacituzumab to pembrolizumab helps them stay cancer-free longer.
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
PHASE3 Homewood, Alabama +4 sites NCT06855277
This trial is looking for adult men with a specific type of prostate cancer called PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Participants will receive a treatment called AAA817 along with other medications to see if it improves their condition.
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
PHASE3 Anchorage, Alaska +4 sites NCT07214779
This trial is looking for women with a specific type of ovarian cancer that hasn't responded to platinum-based treatments. Participants will receive the drug INCB123667 or a chemotherapy chosen by their doctor.
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
PHASE3 Tucson, Arizona +4 sites NCT06712355
This trial is looking for patients with untreated extensive-stage small-cell lung cancer. Participants will receive either BNT327 combined with chemotherapy or a different combination of treatments to see which works better.
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
PHASE2 Goodyear, Arizona +4 sites NCT04613596
This trial is looking for patients with advanced non-small cell lung cancer who have a specific mutation. Participants will receive treatments to see how well they work.
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
PHASE3 Birmingham, Alabama +4 sites NCT05633654
This trial is looking for adults with triple negative breast cancer that remains after surgery and treatment. Participants will receive an experimental treatment combining two medications after recovery from surgery.
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3 Birmingham, Alabama +4 sites NCT05774951
This trial is looking for people with early breast cancer who have completed at least 2 years of standard treatment. Participants will receive camizestrant to see if it helps improve their outcomes compared to standard therapy.
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
PHASE3 Mobile, Alabama +4 sites NCT06393374
This trial is looking for adults with a specific type of breast cancer called triple-negative breast cancer who didn’t have a full response to their initial treatment. They need to have recently had surgery and recovered well, and they should not have certain complicated health issues like severe nerve pain or a known genetic mutation linked to breast cancer. Additionally, the trial is not for people who have serious eye problems or are currently pregnant or breastfeeding.
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
PHASE3 Birmingham, Alabama +4 sites NCT06824467
This trial is looking for women with certain types of ovarian cancer who have had previous chemotherapy. Participants will receive a treatment to see if it helps them live longer without their cancer worsening.
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
PHASE3 Mobile, Alabama +4 sites NCT06952504
This trial is looking for people with advanced or recurring endometrial cancer that has specific characteristics. Participants will receive a combination of two medicines, sacituzumab tirumotecan and pembrolizumab, to see if it helps them live longer or keeps the cancer from worsening.
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
PHASE3 Tucson, Arizona +4 sites NCT06989112
This trial is looking for adults with a specific type of endometrial cancer. Participants will receive either a combination of two new treatments or a standard chemotherapy and immunotherapy to see how well they work.
Recruiting
See all 211 Cancer trials in Louisiana

Where the Cancer studies are in Louisiana

Research sites running the most studies
  • University Medical Center New Orleans, New Orleans40 trials
  • Ochsner Medical Center Jefferson, New Orleans34 trials
  • Mary Bird Perkins Cancer Center, Baton Rouge21 trials
  • Louisiana State University Health Science Center, New Orleans18 trials
  • Louisiana Hematology Oncology Associates LLC, Baton Rouge15 trials
  • East Jefferson General Hospital, Metairie14 trials
By city

Counts are recruiting studies listing at least one site in Louisiana, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Louisiana: common questions

How many Cancer clinical trials are recruiting in Louisiana?
TrialFinder currently lists 211 recruiting Cancer clinical trials with study sites in Louisiana. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Louisiana?
Study sites for the Cancer trials listed on this page include Shreveport. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Louisiana?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Louisiana also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Louisiana?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Cancer Trials in Other States
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming
Helpful Reading
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Louisiana.

Get Matched — Free
No insurance required
About Cancer Trials

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →
Other Conditions in Louisiana
Diabetes Breast Cancer Depression Anxiety Alzheimer's Heart Disease Asthma Multiple Sclerosis Obesity Parkinson's Lupus Hypertension COPD Stroke Arthritis Kidney Disease COVID-19
All trials in Louisiana →